Tissue Repair

TB-500: Research Overview of the Thymosin Beta-4 Fragment

October 2026·8 min read

TB-500 is the name used for a short synthetic peptide modelled on one active region of thymosin beta-4 (Tβ4), a 43-amino-acid protein present in most animal and human cells. Analytical chemistry papers describe TB-500 as the seven-residue sequence LKKTETQ, which corresponds to positions 17 to 23 of Tβ4, with an acetyl group added to its starting end: Ac-LKKTETQ (Esposito 2012; Ho 2012).

That distinction matters when reading the literature. Most of the tissue-repair research people associate with TB-500 was carried out with the full-length Tβ4 protein, not with the seven-residue fragment.

TB-500 and Thymosin Beta-4 Are Not the Same Molecule

  • Thymosin beta-4: 43 amino acids, roughly 4.9 kDa. It is one of the main proteins that bind single actin units (G-actin) inside cells, which helps control how the cell's internal skeleton is built and taken apart (Safer 1991).
  • TB-500 (Ac-LKKTETQ): 7 amino acids, roughly 0.89 kDa. The LKKTETQ stretch sits inside the part of Tβ4 that binds actin, which is why it was chosen as the basis for a smaller synthetic version (Ho 2012).

Because the name is used loosely in the market, the identity result on a batch certificate (mass spectrometry or a matched HPLC reference) is the most reliable way to confirm which molecule a vial contains.

Studied Mechanisms (Mostly From Full-Length Tβ4)

  • Actin binding and cell movement — Tβ4 holds G-actin in reserve, which is linked to how readily cells change shape and migrate (Safer 1991).
  • Wound-model research — in a rat full-thickness skin wound model, Tβ4 applied to the wound or given intraperitoneally increased re-epithelialization by 42% over saline controls at day 4 and by up to 61% at day 7, with more collagen deposition and new blood vessel growth in the treated wounds. The same study found Tβ4 increased keratinocyte migration two- to three-fold in a cell-culture assay (Malinda 1999).
  • Cardiac cell signalling — Tβ4 was shown to form a complex with the proteins PINCH and integrin-linked kinase, activating the survival kinase Akt. In mice after coronary artery ligation, Tβ4 treatment was associated with better early heart-muscle cell survival and cardiac function (Bock-Marquette 2004).
  • Corneal models — in an alkali-injury model of the cornea, Tβ4 was reported to promote wound closure and reduce inflammation (Sosne 2002).

A broad review of this body of work, written by researchers who helped characterize Tβ4, is Goldstein 2012.

What Studies of the Fragment Itself Show

Published research on Ac-LKKTETQ as a separate molecule is much thinner, and most of it comes from anti-doping laboratories, because the product has been misused in horse racing and sport.

  • Identification — a Belgian anti-doping group synthesized Ac-LKKTETQ, confirmed it as the active ingredient in a TB-500 product by high-resolution mass spectrometry, and proposed a detection method for plasma and urine (Esposito 2012).
  • Detection in horses — a Hong Kong racing laboratory developed a liquid chromatography-mass spectrometry method that detects Ac-LKKTETQ and its breakdown products in equine plasma and urine (Ho 2012).
  • Metabolism and activity — a 2024 study traced how TB-500 is broken down in human serum, in enzyme systems and in rats. The main early breakdown product was Ac-LK, and Ac-LKK was detectable for up to 72 hours in rats. In a fibroblast scratch assay, only the breakdown product Ac-LKKTE showed significant wound-closure activity, and the authors suggest earlier reported activity of TB-500 may come from this metabolite rather than the parent peptide (Rahaman 2024).

Human Research Status

Full-length Tβ4 has been studied in clinical trials as an eye-drop formulation for ocular surface conditions (reviewed in Sosne 2018). A PubMed search in October 2026 found no published clinical trials of the TB-500 fragment itself.

Handling in the Lab

TB-500 is supplied as a lyophilized powder. Unopened vials are best stored at −20 °C, protected from light and moisture. After reconstitution with bacteriostatic water, keep the solution at 2–8 °C and avoid repeated freeze–thaw cycles. Our reconstitution guide and Reconstitution Calculator cover the solution-concentration math.

See the TB-500 product page for current batch specifications, or the BPC-157 + TB-500 blend. For the other compound in that blend, read our BPC-157 research overview.

References

  1. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027
  2. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823
  3. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-32. PubMed 1999398
  4. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PubMed 10469335
  5. Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PubMed 15565145
  6. Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-9. PubMed 11950239
  7. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed 22074294
  8. Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024;1235:124033. PubMed 38382158
  9. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99-104. PubMed 30063853
Research Use Only. This article is provided for general research and educational context only. It does not constitute medical advice, and none of the compounds discussed are intended for human or veterinary use.